Literature DB >> 1133848

Naturally occurring human antibody to neuraminidase-treated human lymphocytes. Antibody levels in normal subjects, cancer patients, and subjects with immunodeficiency.

N Rogentine.   

Abstract

Antineuraminidase-treated lymphocyte antibody levels in normal individuals were compared to levels in patients with newly diagnosed malignancies, patients with immunodeficiency syndromes (some of whom subsequently developed cancer), and normal and affected members of multiple malignancy families. No correlation between antibody level and the presence of malignancy was found. In normal individuals, antibody levels were high in childhood and declined with advancing age in accord with behavior of other natural antibodies.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1133848     DOI: 10.1093/jnci/54.6.1307

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  4 in total

1.  Reappearance in vivo of neuraminidase-sensitive sialic acid in L 5222 rat leukemia cells.

Authors:  C Roeder; G Haemmerli; P Sträuli
Journal:  Experientia       Date:  1976-08-15

2.  The heterocytotoxicity of human serum. III. Studies of the serum levels and distribution of activity in human populations.

Authors:  G Glumac; A Mates; D Eidinger
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

3.  Decreased levels of circulating lytic anti-T in the serum of patients with metastatic gastrointestinal cancer: a correlation with disease burden.

Authors:  J Bray; G D MacLean; F J Dusel; T A McPherson
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

4.  Neuraminidase and tumor immunotherapy.

Authors:  H H Sedlacek; F R Seiler; H G Schwick
Journal:  Klin Wochenschr       Date:  1977-03-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.